What is Brief History of Myriad Company?

How did Myriad reshape hereditary cancer testing?

The company’s 1990s breakthrough in isolating BRCA1/2 shifted oncology from reactive care to proactive risk management. Founded in 1991 in Salt Lake City, Myriad expanded from a genomics lab into a diversified leader in genetic testing by 2024.

Myriad moved from patent-driven dominance to a data-focused services model, with 2024 revenues above 820 million USD, and now spans women’s health, oncology, and pharmacogenomics.

What is Brief History of Myriad Company?

Founded in 1991, Myriad’s key milestone was sequencing BRCA1/2 in the mid-1990s, creating the first reliable hereditary breast/ovarian cancer test; its portfolio and market role then expanded globally. See Myriad Porter's Five Forces Analysis

Myriad Genetics was incorporated on May 21, 1991, blending academic genetics and venture capital to commercialize diagnostic tests targeting inherited disease risks.

Founding Story

The company began as a collaboration between university researchers and investors to map disease-associated genes and develop clinical diagnostics.

• Founded on May 21, 1991 — key date in the Myriad Company history
• Founders included Dr. Mark Skolnick, Dr. Walter Gilbert, Peter Meldrum, and Kevin Kinsella
• Initial focus: discover genetic bases of common diseases and secure IP to commercialize tests
• Seed funding led by Venrock enabled lab build-out in Salt Lake City

The founding team targeted BRCA1 as an early flagship project, combining Skolnick’s genealogical datasets with Gilbert’s molecular methods to pursue sequencing and patent strategies during the early Human Genome Project era.

Early business model: gene discovery, patenting variants, and offering diagnostic services; this model aimed to translate genomics into clinical revenue during a period when biotech venture investment was expanding.

Capital and resources: seed rounds from Venrock totaled early multimillion-dollar commitments (initial funding rounds in the low millions of dollars) to equip facilities and hire research staff in the 1990s.

Challenges and strategy: the team overcame skepticism about commercial sequencing by integrating academic credibility with aggressive IP strategy and venture-backed scaling, which defined the Myriad Company founding approach and subsequent Myriad Company timeline milestones.

By positioning itself at the intersection of research and commercialization, the company set a trajectory that led to major events in Myriad Company's past, including pivotal legal and clinical milestones in later years; see a detailed overview at Brief History of Myriad.

Complete Myriad Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Following BRCA1 (1994) and BRCA2 (1995) discoveries, Myriad accelerated from research to commercial diagnostics, completing its 1995 IPO (Nasdaq: MYGN) and launching BRACAnalysis in 1996; institutionalization included a dedicated sales force and a high-throughput clinical lab.

IPO and commercialization

The 1995 IPO provided capital to scale operations and commercialize tests, marking a key milestone in the Myriad Company timeline and enabling rapid market entry for BRACAnalysis in 1996.

BRACAnalysis rollout

BRACAnalysis became the flagship hereditary breast and ovarian cancer diagnostic, processed in a clinical-grade laboratory designed to handle thousands of samples annually with validated accuracy.

Portfolio diversification

During the 2000s and early 2010s Myriad expanded into urology and dermatology, launching tests like Prolaris and Melapanel as part of the evolution of Myriad Company to reduce reliance on hereditary cancer revenues.

Acquisitions to reshape revenue

Strategic acquisitions included Assurex Health for $225,000,000 in 2016 (adding GeneSight) and Counsyl for $375,000,000 in 2018, expanding prenatal and carrier screening capabilities amid patent challenges.

Revenue Streams & Business Model of Myriad

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Myriad Company history traces rapid technical wins and legal upheaval: early BRCA patents delivered market dominance, overturned by the 2013 Supreme Court decision, then a strategic pivot toward multi-gene panels, precision oncology and data-driven services that by 2025 leveraged one of the largest proprietary variant databases to regain market relevance.

The company expanded innovation from single-gene assays to multi-gene panels like MyRisk and integrated tumor-germline workflows, improving clinical utility and payer engagement. By 2023–2025 it emphasized data-scale advantages and companion diagnostics to drive adoption in value-based care.

MyRisk Multi-Gene Panel

Replaced two-gene focus with a broad hereditary cancer panel to increase clinical sensitivity and coverage.

Precise Oncology Solutions

Launched in 2023 to combine germline and somatic data plus companion diagnostics for holistic oncology decision support.

Proprietary Variant Database

Built one of the largest curated variant repositories, containing millions of entries used for interpretation and research by 2025.

Companion Diagnostic Partnerships

Expanded collaborations with pharma to co-develop CDx assays, enhancing reimbursement and clinical uptake.

Digital and Reporting Platforms

Invested in modern reporting software and APIs to integrate genetic results into EHRs and oncology workflows.

Value-Based Care Alignment

Shifted commercial strategy to demonstrate clinical utility and cost-effectiveness to payers and health systems.

Major challenges included the loss of patent-based exclusivity after the 2013 ruling, which precipitated price pressure and increased competition; internal restructuring from 2020 required significant cost management and tech modernization. Regulatory scrutiny and payer coverage negotiations also constrained near-term revenue until new product adoption scaled.

Legal and IP Disruption

The Supreme Court decision removed BRCA patent protection, triggering immediate competition and price erosion. The company had to rebuild a defensible moat via data and services rather than patents.

Revenue and Pricing Pressure

Loss of monopoly led to rapid price declines for BRCA testing and short-term revenue contraction. Recovery required product diversification and payer evidence generation.

Operational Transformation

Modernizing laboratory IT and workflows under the 2020 plan required upfront investment and temporary disruptions. By 2025, upgrades supported scale and improved turnaround times.

Payer Coverage Hurdles

Securing broad reimbursement for multi-gene and tumor profiling products demanded robust real-world evidence and cost-effectiveness data. Negotiations extended sales cycles with health systems.

Competition and Market Saturation

Post-2013 entrants increased market fragmentation, pushing Myriad to compete on clinical utility, service and data rather than price alone. Differentiation depended on proprietary annotations and partnerships.

Data Privacy and Compliance

Maintaining HIPAA, GxP and international data protection compliance for a growing genomic database required sustained investment in security and governance. Ongoing audits and regional regulations increased operational complexity.

For a focused look at the company’s market positioning and commercial playbook see Marketing Strategy of Myriad

Myriad Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Timeline and Future Outlook: a concise chronology of Myriad Company history highlighting key milestones from its 1991 founding to 2025 plans, and a forward-looking view on growth in pharmacogenomics, AI integration, and international expansion.

Market Position and Volumes

GeneSight has tested over 2 million patients to date, underpinning a dominant pharmacogenomics position and contributing to record 2024 volumes.

Regulatory and IP Landscape

The 2013 Supreme Court decision remains a pivotal legal fact shaping patent strategy and competitive dynamics in genetic testing.

Technology Roadmap

Near-term plans include AI integration to aid interpretation of variants of uncertain significance and enhancement of liquid biopsy capabilities.

Commercial Strategy

Strategic initiatives focus on reducing ordering friction, expanding insurance coverage for multi-gene panels, and growing primary care adoption globally.

Further context on the company’s target segments and market approach is available in this article: Target Market of Myriad

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE